Durysta (Bimatoprost)

Generic Name

Bimatoprost

Brand Names

Durysta, Latisse, Lumigan, Zolymbus

FDA approval date: January 26, 2009

Classification: Prostaglandin Analog

Form: Gel, Implant, Solution

What is Durysta (Bimatoprost)?

DURYSTA TM is indicated for the reduction of intraocular pressure in patients with open angle glaucoma or ocular hypertension . DURYSTA TM is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open angle glaucoma or ocular hypertension .

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Enrollment Status: Recruiting

Publish Date: March 05, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,

Enrollment Status: Recruiting

Publish Date: October 20, 2025

Intervention Type: Device, Drug

Study Phase: Phase 3

Summary: This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Enrollment Status: Recruiting

Publish Date: October 20, 2025

Intervention Type: Device, Drug

Study Phase: Phase 3

View All Clinical Trials